promestriene and Syndrome

promestriene has been researched along with Syndrome* in 3 studies

Trials

3 trial(s) available for promestriene and Syndrome

ArticleYear
Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study.
    Clinics (Sao Paulo, Brazil), 2022, Volume: 77

    In this pilot, prospective, randomized, double-blind study, the authors compared the efficacy of oxytocin with promestriene in improving vaginal atrophy of Genitourinary Syndrome of Menopause (GSM).. A total of 51 postmenopausal women with symptoms of GSM were evaluated. They were randomized into two groups: oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.. After the use of the medications, both groups showed significant improvement in the three evaluated FSFI domains (p < 0.05) and there was no significant difference between the groups (p > 0.05). On clinical examination, the medications improved all the evaluated parameters but without statistical significance (p > 0.05). The evaluation of the thickness of the vaginal epithelium showed that both treatments led to increase in the vaginal epithelium (p < 0.05); however, the efficacy of promestriene was higher than that of oxytocin (p < 0.05).. Both medications were effective, however, studies with larger samples and longer follow-ups are needed to confirm the clinical applicability.

    Topics: Atrophy; Double-Blind Method; Estradiol; Female; Humans; Menopause; Oxytocin; Pilot Projects; Postmenopause; Prospective Studies; Syndrome; Treatment Outcome; Vagina

2022
Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial.
    Menopause (New York, N.Y.), 2019, Volume: 26, Issue:8

    The aim of this study was to compare the effects of fractional CO2 laser therapy, promestriene, and vaginal lubricants on genitourinary syndrome treatment and sexual function in postmenopausal women.. We performed a randomized clinical trial including 72 postmenopausal women over the age of 50 years. The women were randomized into three intervention groups to receive one of the following treatments: three sessions of intravaginal fractional CO2 laser therapy; 10 mg of intravaginal promestriene cream 3 times a week; and vaginal lubricant application alone. Vaginal maturation, Vaginal Health Index (VHI) score, and Female Sexual Function Index (FSFI) were evaluated at baseline and after 14 weeks of therapy.. We observed an improvement in the vaginal elasticity, volume, moisture, and pH in the CO2 laser and promestriene groups. The VHI score at 14 weeks was higher in the CO2 laser group (mean score 18.68) than in the promestriene (15.11) and lubricant (10.44) groups (P < 0.001). Regarding vaginal maturation, basal cells were reduced and superficial cells were increased after treatment. This improvement was more significant in the CO2 laser group (P <0.001). The FSFI score only showed improvement in the desire and lubrication domains in the CO2 laser group. There were no differences in total FSFI score among the three treatment groups. There were no adverse effects associated with any of the treatments.. The use of fractional CO2 laser therapy to treat genitourinary syndrome resulted in better short-term effects than those of promestriene or lubricant with respect to improving the vaginal health in postmenopausal women.

    Topics: Administration, Intravaginal; Atrophy; Estradiol; Estrogens; Female; Female Urogenital Diseases; Humans; Lasers, Gas; Lubricants; Middle Aged; Postmenopause; Sexual Dysfunction, Physiological; Syndrome

2019
Urethral syndrome: clinical results with antibiotics alone or combined with estrogen.
    European urology, 1994, Volume: 26, Issue:2

    The urethral syndrome is very frequent in women but the etiology is unknown. In all 77 patients suffering from the syndrome, endoscopy revealed characteristic lesions in the trigonal area. As unidentified bacteria may be responsible, a microbiological investigation was carried out. Wide-spectrum or specific antibiotic therapy was prescribed as required. All patients were also randomized to 2 groups to assess the efficacy of local estrogen therapy. The authors concluded that wide-spectrum antibiotic therapy with macrolide and mepartricin should be the first choice of treatment and that local administration of estrogen does not significantly enhance the benefits achieved through antibiotic therapy. A detailed microbiological investigation is necessary when symptoms persist. Overall a positive result was obtained in 75.32% of the cases (58 patients). The presence of Streptococci negatively influenced the results of specific antibiotic therapy.

    Topics: Adult; Cystitis; Drug Therapy, Combination; Estradiol; Estradiol Congeners; Female; Humans; Josamycin; Logistic Models; Mepartricin; Middle Aged; Syndrome; Treatment Outcome

1994